In8bio Inc.

1 clinical trials · Sponsor

Record	Firm	Date
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma (NCT05664243)	In8bio Inc.	2023-09-08

Every clearance here is in the API, with alerts when new ones post.